Arbutus Biopharma Reports Q3 2024 Results
Ticker: ABUS · Form: 10-Q · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: financials, revenue, biopharma
TL;DR
**Arbutus Biopharma Q3 2024: Revenue flat at $0.00. No change.**
AI Summary
Arbutus Biopharma Corp. reported its financial results for the quarter ended September 30, 2024. The company's revenue from collaboration and contracts for the third quarter of 2024 was $0.00, a decrease from $0.00 in the same period of 2023. For the nine months ended September 30, 2024, revenue from collaboration and contracts was also $0.00, compared to $0.00 for the same period in 2023. The company's fiscal year ends on December 31.
Why It Matters
This filing provides insight into Arbutus Biopharma's revenue generation from its ongoing collaborations and contracts, which is crucial for assessing its financial health and operational progress in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — The company's revenue from collaboration and contracts is zero, indicating potential financial challenges or a focus on research and development without immediate commercial returns.
Key Numbers
- $0.00 — Collaboration and Contracts Revenue (Q3 2024) (Represents the revenue generated from partnerships and agreements during the third quarter of 2024.)
- $0.00 — Collaboration and Contracts Revenue (Nine Months Ended Q3 2024) (Represents the revenue generated from partnerships and agreements for the first nine months of 2024.)
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Filer of the 10-Q report.
- September 30, 2024 (date) — End of the reporting period for the 10-Q.
- 2024 (date) — Year for the reporting period.
- 2023 (date) — Prior year for comparison.
- December 31 (date) — Fiscal year end.
FAQ
What was Arbutus Biopharma's revenue from collaboration and contracts for the third quarter of 2024?
Arbutus Biopharma's revenue from collaboration and contracts for the third quarter of 2024 was $0.00.
How does the Q3 2024 collaboration and contracts revenue compare to Q3 2023?
The collaboration and contracts revenue for Q3 2024 was $0.00, the same as in Q3 2023.
What was the total revenue from collaboration and contracts for the first nine months of 2024?
For the nine months ended September 30, 2024, the revenue from collaboration and contracts was $0.00.
When does Arbutus Biopharma's fiscal year end?
Arbutus Biopharma's fiscal year ends on December 31.
What was the previous name of Arbutus Biopharma Corp.?
Arbutus Biopharma Corp. was formerly known as TEKMIRA PHARMACEUTICALS Corp.
From the Filing
0001447028-24-000087.txt : 20241106 0001447028-24-000087.hdr.sgml : 20241106 20241106160239 ACCESSION NUMBER: 0001447028-24-000087 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241430806 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 10-Q 1 abus-20240930.htm 10-Q abus-20240930 false 0001447028 12/31 2024 Q3 xbrli:shares iso4217:USD iso4217:USD xbrli:shares abus:subsidiary abus:numberOfSegments xbrli:pure abus:product utr:Rate 0001447028 2024-01-01 2024-09-30 0001447028 2024-11-05 0001447028 2024-09-30 0001447028 2023-12-31 0001447028 abus:CollaborationAndContractsMember 2024-07-01 2024-09-30 0001447028 abus:CollaborationAndContractsMember 2023-07-01 2023-09-30 0001447028 abus:CollaborationAndContractsMember 2024-01-01 2024-09-30 0001447028 abus:CollaborationAndContractsMember 2023-01-01 2023-09-30 0001447028 abus:NonCashRoyaltyMember 2024-07-01 2024-09-30 0001447028 abus:NonCashRoyaltyMember 2023-07-01 2023-09-30 0001447028 abus:NonCashRoyaltyMember 2024-01-01 2024-09-30 0001447028 abus:NonCashRoyaltyMember 2023-01-01 2023-09-30 0001447028 2024-07-01 2024-09-30 0001447028 2023-07-01 2023-09-30 0001447028 2023-01-01 2023-09-30 0001447028 us-gaap:CommonStockMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001447028 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001447028 2024-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001447028 2024-04-01 2024-06-30 0001447028 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001447028 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001447028 us-gaap:CommonStockMember 2024-06-30 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001447028 us-gaap:RetainedEarningsMember 2024-06-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001447028 2024-06-30 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001447028 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001447028 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001447028 us-gaap:CommonStockMember 2024-09-30 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001447028 us-gaap:RetainedEarningsMember 2024-09-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001447028 us-gaap:CommonStockMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-12-31 0001447